Thursday, January 27, 2022 Daily Archives

Accelerate Biologic Process Development and GMP Manufacturing Using In-Line Concentration Measurement

This webcast features: Ramsey Shanbaky, Associate Director, Bioprocess Applications, Repligen In-process measurement is the key to process monitoring and control. It can save time and money by helping you identify key aspects of your process in real-time. In this webcast, we will demonstrate how the CTech™ FlowVPX™ Slope Spectroscopy System, when directly integrated in one or more locations of a process stream, has helped reveal process characteristics that until now have been hidden due to the limitations of the most…

Facilitating Workforce Development: A case study on improving single-use training through vendor and end-user collaboration

Discover how Pall Corporation and Lonza collaborated to improve single-use technology training for operators using a blended approach to learning. This article presents: The importance of SUT training for operators. Why a blended approach ensures that operators get the training they need in the format that best suits their learning style. How collaboration between suppliers and biomanufacturers can shorten training program development timelines and increase the quality of training tools. How Pall and Lonza developed a digital training approach together.…

CDMO Arranta buys Cytiva single-use tech for mRNA production

Live biologics CDMO¬†Arranta¬†Bio has bought a single-use manufacturing platform from¬†Cytiva¬†for the production of¬†mRNA vaccines.¬† The purchase is part of a $110 million investment by¬†Arranta¬†at its manufacturing and development facility in Watertown, Massachusetts. The CDMO also plans to open a¬†dedicate¬†space for lipid nanoparticle formulation¬† Joe Makowiecki from¬†Cytiva, told us ‚ÄúThis is the first¬†FlexFactory¬†for an mRNA product,‚ÄĚ adding that it will¬†‚Äúprovide¬†Arranta¬†the flexibility to manufacture mRNA vaccines and therapies from in vitro transcription (IVT) to drug product aseptic fill. ‚ÄĮ¬† He predicted that…

Fujifilm Dio signs long term supply deal and buys plant from Atara

Fujifilm Diosynth Biotechnologies will¬†buy¬†Atara Biotherapeutics‚Äô¬†T-Cell operations and facility in¬†Thousand Oaks, California for $100 million.¬† The deal will also see the¬†contract development and manufacturing organization (CDMO)¬†sign a long-term supply agreement covering both clinical and commercial production of Atara‚Äôs range allogeneic cell therapies.¬†¬† Specific candidates will include¬†tabelecleucel, ATA188 for multiple sclerosis and the allogeneic CAR T therapies, ATA3271 and ATA3219. Fujifilm Diosynth Biotechnologies also said it will expand use of the Thousand Oaks facility ‚Äď which is known as ATOM¬†‚Ästto manufacture a…